1. Home
  2. FGEN vs PYPD Comparison

FGEN vs PYPD Comparison

Compare FGEN & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FGEN
  • PYPD
  • Stock Information
  • Founded
  • FGEN 1993
  • PYPD 2008
  • Country
  • FGEN United States
  • PYPD Israel
  • Employees
  • FGEN N/A
  • PYPD N/A
  • Industry
  • FGEN Biotechnology: Pharmaceutical Preparations
  • PYPD Medical/Dental Instruments
  • Sector
  • FGEN Health Care
  • PYPD Health Care
  • Exchange
  • FGEN Nasdaq
  • PYPD Nasdaq
  • Market Cap
  • FGEN 34.5M
  • PYPD 30.1M
  • IPO Year
  • FGEN 2014
  • PYPD 2020
  • Fundamental
  • Price
  • FGEN $0.55
  • PYPD $2.95
  • Analyst Decision
  • FGEN
  • PYPD Strong Buy
  • Analyst Count
  • FGEN 0
  • PYPD 2
  • Target Price
  • FGEN N/A
  • PYPD $10.50
  • AVG Volume (30 Days)
  • FGEN 753.5K
  • PYPD 21.4K
  • Earning Date
  • FGEN 02-24-2025
  • PYPD 02-12-2025
  • Dividend Yield
  • FGEN N/A
  • PYPD N/A
  • EPS Growth
  • FGEN N/A
  • PYPD N/A
  • EPS
  • FGEN N/A
  • PYPD N/A
  • Revenue
  • FGEN $180,015,000.00
  • PYPD N/A
  • Revenue This Year
  • FGEN $21.91
  • PYPD N/A
  • Revenue Next Year
  • FGEN N/A
  • PYPD N/A
  • P/E Ratio
  • FGEN N/A
  • PYPD N/A
  • Revenue Growth
  • FGEN 16.15
  • PYPD N/A
  • 52 Week Low
  • FGEN $0.18
  • PYPD $2.37
  • 52 Week High
  • FGEN $2.80
  • PYPD $6.58
  • Technical
  • Relative Strength Index (RSI)
  • FGEN 58.51
  • PYPD 47.49
  • Support Level
  • FGEN $0.46
  • PYPD $2.75
  • Resistance Level
  • FGEN $0.51
  • PYPD $3.22
  • Average True Range (ATR)
  • FGEN 0.04
  • PYPD 0.30
  • MACD
  • FGEN 0.00
  • PYPD -0.01
  • Stochastic Oscillator
  • FGEN 72.57
  • PYPD 33.67

About FGEN FibroGen Inc

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.

About PYPD PolyPid Ltd.

PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.

Share on Social Networks: